中央研究院 Logo

Mark Kao is a toxicologist graduated from North Carolina State University. He then went on to hold various research positions at NIH, Cornell University, Bayer, American Cyanamid, and Wyeth. He was the Scientific Director and a preclinical development leader at Janssen Pharmaceutical, a division of Johnson and Johnson, for almost two decades before his retirement in 2020. Mark has published 24 peer reviewed papers in Pharmacokinetics, toxicology, and drug development.  Mark was the former President of Taiwanese American Association of Biotechnology (TAAB). Mark is currently the Principal of Kao Preclinical Consulting Inc. and is a consultant of several government agencies and private pharma companies in Taiwan.